US Patent Issued for iBio’s Method of Boosting Anti-fibrotic Endostatin-derived Peptides

US Patent Issued for iBio’s Method of Boosting Anti-fibrotic Endostatin-derived Peptides
4.6
(38)

iBio has received a U.S. patent for its method of increasing the amount and quality of endostatin-derived peptides generated from the company’s plant-based FastPharming protein production system.

These peptides, which have been shown to possess strong anti-fibrotic or anti-scarring properties, make up part of IBIO-100, an experimental therapy that iBio is currently developing for the treatment of fibrotic disorders, including idiopathic pulmonary fibrosis and systemic scleroderma.

The patent (No. 10,844,392), titled “Materials and Methods for Producing Endostatin Fusion Polypeptides in Plant Cells,” covers a total of 19 claims with detailed instructions on how to enhance the production and quality of these peptides in plants, and it will allow iBio to retain the exclusive intellectual rights over these methods until June 2036.

“This patent, and the technologies it covers, advances our work on therapeutic candidates for treating fibrotic disorders by increasing the number of antifibrotic peptide variants that we may select for clinical development,” Tom Isett, chairman and CEO of iBio, said in a press release.

“iBio can also apply certain claims to other IgG [immunoglobulin G]-based molecules manufactured using our FastPharming System, thereby creating the opportunity to secure additional intellectual property based upon composition of matter,” Isett added.

Endostatin is an extracellular matrix component that is known to possess strong anti-cancer properties and to inhibit the growth of cells lining blood vessels. Of note, the extracellular matrix is the network of proteins and other molecules that surrounds and supports cells in tissues.

When given orally to animal models, endostatin-derived peptides were able to halt and even reverse tissue scarring, according to a study published in 2012, by Carol Feghali-Bostwick, PhD, from the Medical University of South Carolina, and colleagues. Following these observations, iBio acquired the licenses and intellectual rights over these patented compounds from Feghali-Bostwick and started developing its own endostatin-derived peptides.

IBIO-100 resulted from the fusion of these anti-fibrotic endostatin-derived peptides with a portion of human immunoglobulin G1, the most common subclass of antibodies circulating in the blood.

In preclinical studies, IBIO-100 was found to be effective at reducing tissue scarring in a mouse model of pulmonary fibrosis, as well as in human lung tissues.

The company is now planning to conduct additional studies next year to support the submission of an investigational new drug application for IBIO-100 so it can be authorized to start clinical trials.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 110

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • collapsed lung and IPF
  • fatigue and IPF
  • taladegib
  • patent for iBio

How useful was this post?

Click on a star to rate it!

Average rating 4.6 / 5. Vote count: 38

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?